Drug Profile
Interleukin-2 liposomal - Therapeutics 2000
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Therapeutics 2000
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 02 Nov 1998 Preclinical development for Lung cancer in USA (Inhalation)